Stay updated with breaking news from Timra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IMARA (NASDAQ:IMRA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare […] ....
IMARA Inc. (NASDAQ:IMRA – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 194,400 shares, a decline of 26.9% from the April 30th total of 265,800 shares. Based on an average daily volume of 383,300 shares, the days-to-cover ratio is presently […] ....
IMARA (NASDAQ:IMRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The brokerage presently has a $1.50 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 30.43% from the company’s current price. […] ....